GH stimulation, pediatric growth, endocrinology
Discontinued (Geref); compounded
~1986 (IV, SC, intranasal)
SC, IV, Intranasal, Sublingual
Overview
Sermorelin is a synthetic 29-amino acid analogue of growth hormone-releasing hormone (GHRH), corresponding to the first 29 amino acids of endogenous GHRH (GHRH 1–29 amide). It functions as an agonist at pituitary GHRH receptors, stimulating the pulsatile release of endogenous growth hormone (GH). Human pharmacology across intravenous, subcutaneous, and intranasal routes was established in studies dating to 1986 [1].
Sermorelin was marketed in the United States under the brand name Geref (Serono) and was FDA-approved for the diagnosis and treatment of GH deficiency in children. The FDA later documented that Geref was not withdrawn from the market for safety or effectiveness reasons; it was discontinued commercially [2]. Today it is widely compounded by specialized pharmacies for use in adult anti-aging and longevity medicine contexts.
Unlike exogenous recombinant human GH (rhGH), sermorelin acts upstream at the pituitary; it does not directly administer GH, but instead prompts the body's own pituitary to release GH in a pulsatile, physiologically modulated fashion. This distinction is frequently cited in clinic contexts, though whether it confers meaningful clinical advantages over rhGH in adult use is not established by randomized controlled data [6].
Research Areas and Claims
Sermorelin's evidence base spans pediatric endocrinology (its original approved indication) through adult research in older populations. Longevity-clinic claims extend well beyond the published evidence.
-
GH Stimulation (Endocrine Endpoint): Sermorelin reliably stimulates GH secretion when the pituitary is responsive. This is its best-established effect, demonstrated across multiple routes in normal and GH-deficient subjects [1][5].
-
Pediatric Growth: In GH-deficient children, once-daily SC sermorelin accelerated growth velocity in the first year of treatment. This represents its original FDA-approved application [3][8].
-
IGF-1 Elevation in Older Adults: Twice-daily GHRH(1-29) increased GH and IGF-I in older men, representing endocrine evidence of activity in aging populations [5][9].
-
Anti-Aging, Sleep, Body Composition (Clinic Claims): Common claims in compounding and longevity clinic contexts (improved sleep quality, body composition, recovery, and "anti-aging") are not established by robust randomized trial evidence. Translating GH/IGF-1 elevation into these outcomes remains unvalidated for sermorelin specifically [6][7].
Mechanism of Action
Sermorelin's mechanism is well-characterized at the receptor level. Downstream physiological effects depend on individual pituitary responsiveness, age, and baseline GH axis function.
- GHRH Receptor Agonism: Sermorelin binds to GHRH receptors on pituitary somatotroph cells, mimicking the action of endogenous GHRH. This directly stimulates pulsatile GH secretion [1][3].
- Pulsatile GH Release: By acting at the pituitary rather than delivering GH directly, sermorelin preserves the physiological pulsatility and negative-feedback regulation of the GH axis. Somatostatin tone and other regulatory inputs remain active [5].
- Downstream IGF-1 Effects: GH secreted in response to sermorelin stimulates hepatic IGF-1 production. IGF-1 mediates many of the growth-promoting and anabolic effects attributed to the GH axis, and is the primary downstream biomarker monitored in clinical use [9].
Clinical Trials
Sermorelin has a meaningful published evidence base relative to many research peptides, concentrated in pediatric GH deficiency and endocrine physiology studies in older adults. Notably, no large randomized controlled trials demonstrate hard longevity endpoints (mortality, cardiovascular events, frailty reduction) in healthy adults.
| Study & Year | Population | Route / Dose | Key Finding | Ref |
|---|---|---|---|---|
| Route/PK/PD (1986) | Normal men | IV, SC, Intranasal | GHRH(1-29) stimulated GH via all three routes; established human pharmacology | [1] |
| Older men (1992) | Older men | SC, twice-daily | Increased GH and IGF-I; demonstrated pituitary responsiveness in aging | [5] |
| Pediatric ISS (1994) | Children, idiopathic short stature | SC, 12-month | Variable growth response; some pediatric populations benefit | [8] |
| GH-deficient children (1996) | GH-deficient children | SC, once-daily | Accelerated growth velocity in year one (original FDA-approved use) | [3] |
| Age-advanced adults (1997) | Older men and women | SC, longer-term | Endocrine and metabolic effects reported; not longevity outcomes | [9] |
| Dosing frequency (1997) | Older adults | SC, nightly vs. multi-dose | Nightly dosing may not fully replicate multi-dose endocrine effects | [10] |
Missing-Trials Note: No robust randomized controlled trials demonstrate that sermorelin improves hard longevity endpoints (mortality, cardiovascular events, or frailty) in healthy adults. Most published evidence addresses endocrine physiology and pediatric growth outcomes [3][5][6].
Administration Methods
- Subcutaneous (SC): The most common clinical and compounding route. Often administered nightly to align with physiological nocturnal GH secretion patterns [3][4].
- Intravenous (IV): Used in endocrine stimulation-testing and research protocols; not typical for ongoing compounding use [1].
- Intranasal: Demonstrated as a feasible route for GH stimulation in early human pharmacology work; available from some vendors as a pre-mixed nasal spray [1].
- Sublingual (tablets): Available from some vendors; bioavailability via this route has not been established in published human pharmacokinetic studies.
Important Safety & Regulatory Information
- FDA Status: Discontinued, Not Current: Sermorelin (Geref) was FDA-approved but is no longer commercially marketed. The FDA documented it was not withdrawn for safety or effectiveness reasons [2]. Compounded versions operate under a different regulatory framework and do not carry the same approval status.
- No Standardized Anti-Aging Dosing: No guideline-endorsed dosing schedule exists for sermorelin in healthy adults for anti-aging purposes. Common nightly SC dosing in compounding practice is not validated by randomized controlled evidence [6].
- Sublingual / Intranasal Bioavailability Uncertain: Sublingual tablets and intranasal preparations are commercially available as research products, but robust human PK data validating peptide bioavailability via these oral/mucosal routes for sermorelin has not been established in the published literature.
- GH Axis Risks: Stimulating GH/IGF-1 elevation carries theoretical risks including potential promotion of pre-existing neoplasms, insulin resistance, fluid retention, and joint pain. These apply to GHRH-agonist approaches as well as direct GH administration. Individuals with active cancer or diabetes should exercise particular caution.
- WADA: GHRH analogues including sermorelin are prohibited by the World Anti-Doping Agency under the S2 category (Peptide hormones, growth factors, related substances, and mimetics).
Market Overview
Please note: The following data is based on February 2026 pricing across surveyed vendors. All products are sold strictly as research chemicals. Prices fluctuate based on volume, batch, purity, and presentation.
Injectable
Lyophilized PowderReconstituted for SC injection. Common vial sizes: 2mg, 5mg, 15mg.
- Price Range: $7.60 – $19.80 per mg
- Typical Sizes: 2mg, 5mg, 15mg, 20mg (kit)
- Vendors with pricing: 3 surveyed
Intranasal
Nasal SprayPre-mixed nasal spray, 100 mcg per actuation. ~100 sprays per bottle.
- Price: ~$12.68 per mg
- Typical Sizes: 10mg per bottle
- Vendors with pricing: 1 surveyed
Sublingual
Tablets200 mcg per sublingual tablet. Bioavailability via this route is not established in published PK data.
- Price Range: $23.67 – $24.95 per mg
- Typical Sizes: 2mg (10 tabs) / 4mg (20 tabs)
- Vendors with pricing: 1 surveyed
Vendor Directory
Data collected February 2026. Tables split by formulation route. Vendors without public pricing are noted separately.
Injectable: Lyophilized Powder (SC)
| Vendor | Sizes (mg) | Price Range ($/mg) | Website |
|---|---|---|---|
| Peptide Sciences | 2 / 5 / 15 | $7.60 – $17.50 | peptidesciences.com |
| Swiss Chems | 2 / 20 (10×2mg kit) | $11.70 – $12.98 | swisschems.is |
| Pure Rawz | 2 / 10 | $10.73 – $19.80 | purerawz.co |
Intranasal: Nasal Spray (100 mcg/spray)
| Vendor | Format | Size (mg) | Price ($/mg) | Website |
|---|---|---|---|---|
| Pure Rawz | Pre-mixed nasal spray (100 mcg/spray) | 10 (~100 sprays) | $12.68 | purerawz.co |
Sublingual: Tablets (200 mcg/tab)
| Vendor | Format | Size (mg) | Price ($/mg) | Website |
|---|---|---|---|---|
| Pure Rawz | Sublingual tabs (200 mcg/tab × 10) | 2 | $24.95 | purerawz.co |
| Pure Rawz | Sublingual tabs (200 mcg/tab × 20) | 4 | $23.67 | purerawz.co |
B2B / Wholesale: No Public Pricing
| Vendor | Status | Website |
|---|---|---|
| ZLZ Peptide | B2B / wholesale only | zlzpeptide.com |
| SRY Labs | B2B / wholesale only | srylab.bio |
| Qing Li Peptide | B2B / wholesale only | qinglishangmao.com |
* Data Notes: Data collected February 2026. All products sold strictly for in-vitro research purposes. Prices subject to change. $/mg calculated from listed catalog price divided by total mg per unit.
References
- Hoffman AR, Crowley WF Jr, Valverde I, Frohman LA. "Stimulation of growth hormone secretion by growth hormone-releasing hormone (GHRH) administered via intravenous, subcutaneous, and intranasal routes in normal men." (1986). PubMed
- U.S. Food and Drug Administration. "Drugs@FDA: Geref (Sermorelin Acetate): Discontinued Drug Product." FDA Drugs@FDA
- Thorner MO, et al. "Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy." (1996). PubMed
- Walker RF. "Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?" (2006). Clin Interv Aging. PMC2682418
- Corpas E, Harman SM, Blackman MR. "Human growth hormone and human aging." (1993). Endocr Rev. PubMed 8491152
- Sigalos JT, Pastuszak AW. "The Safety and Efficacy of Growth Hormone Secretagogues." (2018). Sex Med Rev. PMC5632578
- Associated Press. "A closer look at the unapproved peptide injections promoted by influencers and celebrities." (Nov 14, 2025)
- Lanes R. "Long-term outcome of growth hormone therapy in children with idiopathic short stature." (1994). PubMed
- Vittone J, et al. "Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men." (1997). Metabolism. PubMed 9225826
- Khorram O, et al. "Effects of long-term administration of GHRH-(1-29)-NH2 in aged women and men." (1997). J Clin Endocrinol Metab. PubMed 9284703